Hot or Not, Stock Market Edition: 04/17/2026

Happy Friday. Here are the stock stories we're following today:

• Hot: BioCryst Pharmaceuticals (BCRX) picks up the pace; Lear (LEA) benefits from a favorable macro setup
• Not: Bitcoin miner Bitdeer Technologies (BTDR) takes an alarming turn; Huntsman (HUN) faces significant headwinds 

P.S. For more stocks making moves, check out our Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...

🔥 HOT: Auto parts maker Lear (LEA) is benefiting from a favorable macro setup as global auto production stabilizes and long-term trends like vehicle electrification and advanced interior systems continue to drive demand. That powerful industry tailwind is showing up in the data. Right now, Lear holds a Zen Rating of A (Strong Buy) and actually ranks in the top 2% of over 4,600 stocks based on a 115-factor analysis. The company ranks #1 in the Auto Parts industry and delivers a well-rounded profile with strong grades across Growth, Value, Safety, and Sentiment. All said? With industry momentum improving and Lear leading the pack on fundamentals, this is a high-quality name positioned for a potential breakout.

🥶 NOT: Chemical manufacturer Huntsman (HUN) is facing a tough macro setup as industrial chemical demand remains uneven and tied to sluggish global manufacturing — hardly a strong backdrop for a cyclical stock. While shares recently spiked sharply, the move looks more like a short-term bounce than a real shift in fundamentals. The data confirms it: Huntsman holds a Zen Rating of D (Sell), with dismal Component Grades: D Grades for Growth, Sentiment, and Value, signaling broad weakness across the board. It also ranks near the bottom of its industry, meaning it’s lagging peers rather than leading them. The bottom line? Without improving fundamentals, these spikes tend to fade — and this one likely will too. (P.S. If you like updates like this, check out our recent video: 3 Stocks to Buy on the Dip + 1 to Avoid)

🔥 HOT:  Biotech player BioCryst Pharmaceuticals (BCRX) is benefiting from a favorable macro backdrop as biotech sentiment improves and investors rotate back into high-upside healthcare plays. That strength is showing up in the data: BioCryst holds a Zen Rating of A (Strong Buy) and currently ranks in the top 2% of the 4600+ stocks we track. Looking at the Component Grades, it shines with A Grades for Financials and Value and B Grades for Growth and Sentiment — a strong, well-rounded profile. Momentum has been solid overall, with the stock trading well above key long-term levels despite recent volatility, and an upcoming earnings report adds a clear near-term catalyst. The bottom line? With improving sector tailwinds, strong fundamentals, and momentum still intact, this looks like a high-quality biotech play with room to run.

🥶 NOT:  Bitcoin miner Bitdeer Technologies (BTDR) is running into a tougher macro backdrop as Bitcoin mining economics tighten and volatility in crypto prices makes profitability harder to sustain — especially for capital-intensive players. While the company posted strong production growth and the stock has seen short-term pops, those moves aren’t backed by durable fundamentals. The data tells the real story: Bitdeer holds a Zen Rating of D or Sell, with Component Grades that raise alarm bells: F Grades for Financials and Sentiment and D Grades for Momentum, Safety, Value, and AI. This is a broad-based breakdown across nearly every key factor, despite an A Grade for Growth. It also ranks near the bottom of its industry, signaling clear underperformance versus peers. The bottom line? Avoid for now. Production headlines and hardware launches may drive temporary spikes, but without solid financial footing, those gains tend to fade fast.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.